Akeso (Cayman) Biopharma announced on June 3, 2024 that it has revised its licensing agreement with Summit Therapeutics Inc. regarding its bispecific antibody drug, AK112 (PD-1/VEGF). The revised agreement expands the original licensed area to include the Americas, Middle East, and Africa, giving Summit exclusive rights to develop and commercialize AK112 in these regions. Akeso will receive an upfront payment and milestone payments totaling 70 million USD, as well as sales royalties from the newly licensed areas. In addition, the two companies will enhance cross-regional cooperation, sharing clinical trial data and marketing authorization documents to accelerate AK112's global regulatory registration and commercialization. AK112 is a PD-1/VEGF bispecific tumor immunotherapy drug independently developed by Akeso, which was approved for sale in China on May 24, 2024 and is currently undergoing multiple Phase III clinical trials.

Akeso (Cayman) Biopharma announced on June 3, 2024 that it has revised its licensing agreement with Summit Therapeutics Inc. regarding its bispecific antibody drug, AK112 (PD-1/VEGF). The revised agreement expands the original licensed area to include the Americas, Middle East, and Africa, giving Summit exclusive rights to develop and commercialize AK112 in these regions. Akeso will receive an upfront payment and milestone payments totaling 70 million USD, as well as sales royalties from the newly licensed areas. In addition, the two companies will enhance cross-regional cooperation, sharing clinical trial data and marketing authorization documents to accelerate AK112's global regulatory registration and commercialization. AK112 is a PD-1/VEGF bispecific tumor immunotherapy drug independently developed by Akeso, which was approved for sale in China on May 24, 2024 and is currently undergoing multiple Phase III clinical trials.